Abstract
On May 2, the FDA ordered that all antidepressant medications carry an expanded black-box warning incorporating information about an increased risk of suicidal symptoms in young adults 18 to 24 years of age. Dr. Richard Friedman and Andrew Leon write that this new label has the potential to confuse both patients and physicians. Dr. Andrew Leon discusses the expansion of the black-box warning for antidepressants to cover the risk of suicidality among young adults, the suicidality risk associated with depression, and the data available for assessing these risks. Dr. Leon is a professor of biostatistics in psychiatry and a professor of public health at Weill Cornell Medical College, New York, and a member of the FDA's Psychopharmacologic Drugs Advisory Committee.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
